Press release
Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer
WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on
About this update from Monopar Therapeutics Inc.
[{"type":"text","content":"WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar’s global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization to acquisition by Fortune Global 1000 firms. These include founding two successful diagnostic imaging companies, Sensant Corp. and American Biooptics, and leading both through acquisitions, by Siemens and Olympus, respectively. His leadership experience also includes acting as startup CEO of a critical care company, SonarMed, which was acquired by Medtronic. He has managed manufacturing and quality systems implementation, execution of multi-center clinical trials, and regulatory clearances for new technologies in Europe and the US. Mr. Cittadine received his BA, BS, and MS from Stanford and an MBA from Northwestern’s Kellogg School of Management. “We are very pleased to welcome Andrew. He is a proven healthcare leader and a strong addition to our executive team,” said Chandler Robinson, MD, Chief Executive Officer of Monopar. “This is an exciting time at Monopar. They have a well-balanced and promising portfolio of earlier and later stage drug candidates. I’m honored to join this talented and committed team in developing these potentially life-changing treatments for cancer patients,” said Mr. Cittadine. About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, vi...